Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Azitra, Inc.

  • BRANFORD, Connecticut
  • Public · NYSE: AZTR
  • 13 employees
$3.4MMarket cap
$0Revenue · FY2025
-$11.0MNet income
13Employees
AZTRNYSE
2023IPO

About Azitra, Inc.

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$0
Net income
-$11.0M
Total assets
$5.0M
Market cap
$3.4M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: AZTR

15-minute delayed · data by Polygon.io

Market cap
$3.4M
Open
Day range
Prev close
Volume
IPO date
Jun 16, 2023

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Azitra, Inc..

Write a review
Explore

Similar companies

Browse all →